Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | ubiquitin activating enzyme, putative | 0.0239 | 0.2488 | 1 |
Brugia malayi | ThiF family protein | 0.0079 | 0.0205 | 0.0138 |
Toxoplasma gondii | NEDD8-activating enzyme E1 catalytic subunit | 0.0753 | 0.9827 | 1 |
Echinococcus multilocularis | NEDD8 activating enzyme E1 catalytic subunit | 0.0753 | 0.9827 | 1 |
Trypanosoma brucei | ubiquitin-activating enzyme E1, putative | 0.0076 | 0.0157 | 0.0359 |
Echinococcus granulosus | ubiquitin modifier activating enzyme 1 | 0.0167 | 0.1465 | 0.143 |
Trichomonas vaginalis | ubiquitin-activating enzyme E1c, putative | 0.0134 | 0.0989 | 0.1403 |
Schistosoma mansoni | sumo-1-activating enzyme E1a | 0.0079 | 0.0205 | 0.0138 |
Entamoeba histolytica | ubiquitin-activating enzyme E1 1, putative | 0.0134 | 0.0989 | 0.0942 |
Trypanosoma brucei | ubiquitin-activating enzyme E1, putative | 0.0099 | 0.0483 | 0.1709 |
Brugia malayi | Ectopic membrane ruffles in embryo protein 1 | 0.0753 | 0.9827 | 1 |
Loa Loa (eye worm) | ectopic membrane ruffles in embryo protein 1 | 0.0753 | 0.9827 | 1 |
Loa Loa (eye worm) | ube1-prov protein | 0.0167 | 0.1465 | 0.143 |
Plasmodium falciparum | NEDD8-activating enzyme E1 catalytic subunit, putative | 0.0239 | 0.2488 | 1 |
Toxoplasma gondii | hypothetical protein | 0.0079 | 0.0205 | 0.0138 |
Schistosoma mansoni | clathrin coat associated protein ap-50 | 0.0111 | 0.0663 | 0.0608 |
Echinococcus granulosus | ubiquitin modifier activating enzyme 6 | 0.0167 | 0.1465 | 0.143 |
Echinococcus granulosus | NEDD8 activating enzyme E1 catalytic subunit | 0.0753 | 0.9827 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0071 | 0.0083 | 0.0332 |
Trichomonas vaginalis | molybdopterin biosynthesis moeb protein, putative | 0.0239 | 0.2488 | 0.3596 |
Echinococcus multilocularis | SUMO activating enzyme subunit 1 | 0.0079 | 0.0205 | 0.0138 |
Leishmania major | hypothetical protein, conserved | 0.0071 | 0.0083 | 0.0052 |
Trichomonas vaginalis | ubiquitin-activating enzyme E1, putative | 0.007 | 0.007 | 0.0058 |
Schistosoma mansoni | hypothetical protein | 0.0071 | 0.0083 | 0.0013 |
Trichomonas vaginalis | ubiquitin-activating enzyme E1 X, putative | 0.0071 | 0.0092 | 0.0089 |
Loa Loa (eye worm) | hypothetical protein | 0.0071 | 0.0083 | 0.0013 |
Trichomonas vaginalis | ubiquitin-activating enzyme E1, putative | 0.0546 | 0.6863 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0079 | 0.0205 | 0.0138 |
Schistosoma mansoni | clathrin coat associated protein ap-50 | 0.0111 | 0.0663 | 0.0608 |
Trypanosoma cruzi | ubiquitin activating enzyme, putative | 0.0239 | 0.2488 | 1 |
Toxoplasma gondii | kringle domain-containing protein | 0.0071 | 0.0083 | 0.0013 |
Brugia malayi | ube1-prov protein | 0.0167 | 0.1465 | 0.143 |
Giardia lamblia | Ubiquitin-conjugating enzyme E1 | 0.0099 | 0.0483 | 0.5 |
Trypanosoma brucei | NEDD8 activating enzyme subunit, putative | 0.0239 | 0.2488 | 1 |
Schistosoma mansoni | ubiquitin-activating enzyme E1C | 0.0753 | 0.9827 | 1 |
Trypanosoma cruzi | ubiquitin-activating enzyme E1, putative | 0.0099 | 0.0483 | 0.1942 |
Entamoeba histolytica | ubiquitin-activating enzyme, putative | 0.0167 | 0.1465 | 0.143 |
Leishmania major | ubiquitin-activating enzyme e1, putative | 0.0099 | 0.0483 | 0.1709 |
Plasmodium vivax | ubiquitin activating enzyme, putative | 0.0079 | 0.0205 | 0.0508 |
Schistosoma mansoni | ubiquitin-activating enzyme E1 | 0.0139 | 0.1054 | 0.1009 |
Plasmodium falciparum | ubiquitin-activating enzyme E1 | 0.0167 | 0.1465 | 0.5747 |
Leishmania major | ubiquitin-activating enzyme e1, putative | 0.0076 | 0.0157 | 0.0359 |
Echinococcus granulosus | tissue type plasminogen activator | 0.0071 | 0.0083 | 0.0013 |
Loa Loa (eye worm) | TK/ROR protein kinase | 0.0071 | 0.0083 | 0.0013 |
Entamoeba histolytica | ubiquitin-activating enzyme, putative | 0.0753 | 0.9827 | 1 |
Trypanosoma cruzi | NEDD8-activating enzyme E1 regulatory subunit, putative | 0.007 | 0.007 | 0.0281 |
Brugia malayi | Kringle domain containing protein | 0.0071 | 0.0083 | 0.0013 |
Echinococcus multilocularis | ubiquitin modifier activating enzyme 6 | 0.0167 | 0.1465 | 0.143 |
Trichomonas vaginalis | ubiquitin-activating enzyme E1, putative | 0.0134 | 0.0989 | 0.1403 |
Plasmodium vivax | ubiquitin-activating enzyme E1C, putative | 0.0239 | 0.2488 | 1 |
Trypanosoma cruzi | ubiquitin activating enzyme, putative | 0.0239 | 0.2488 | 1 |
Brugia malayi | Protein kinase domain containing protein | 0.0071 | 0.0083 | 0.0013 |
Echinococcus multilocularis | ubiquitin modifier activating enzyme 1 | 0.0167 | 0.1465 | 0.143 |
Plasmodium falciparum | SUMO-activating enzyme subunit 1 | 0.0079 | 0.0205 | 0.0508 |
Trypanosoma cruzi | ubiquitin-activating enzyme E1, putative | 0.0099 | 0.0483 | 0.1942 |
Trichomonas vaginalis | ubiquitin-activating enzyme E1, putative | 0.007 | 0.007 | 0.0058 |
Echinococcus granulosus | SUMO activating enzyme subunit 1 | 0.0079 | 0.0205 | 0.0138 |
Trichomonas vaginalis | ubiquitin-activating enzyme E1, putative | 0.0134 | 0.0989 | 0.1403 |
Echinococcus multilocularis | tissue type plasminogen activator | 0.0071 | 0.0083 | 0.0013 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MIC (functional) | = 50 ug ml-1 | Antifungal activity against Candida albicans after 72 to 96 hr by two-fold serial dilution method | ChEMBL. | No reference |
MIC (functional) | = 50 ug ml-1 | Antifungal activity against Cryptococcus neoformans after 72 to 96 hr by two-fold serial dilution method | ChEMBL. | No reference |
MIC (functional) | = 50 ug ml-1 | Antibacterial activity against Escherichia coli after 24 hr by two-fold serial dilution method | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.